Researchers reported a pan-cancer single-cell atlas that links therapy resistance and immunotherapy response differences to sex-biased SPP1+ macrophage crosstalk with tumor cells. The study describes immune interactions that vary between male and female tumor microenvironments, pointing to a macrophage population marked by SPP1 that can shape how immune checkpoints perform. The atlas-based approach is positioned as an interpretable map of cell states rather than a purely correlative biomarker effort. For drug developers, the work suggests a more granular immuno-oncology strategy—potentially stratifying patients not only by tumor genomics but also by immune cell programs that can differ by sex. The provided coverage emphasizes clinical relevance through the link to prognosis and immunotherapy guidance, with SPP1+ macrophage signaling offered as a route to refine future combination or targeting efforts.